Salute e Benessere
GMP Cell Therapy Consumables Market to Reach USD 114.4 Million by 2035, with CAGR 28.9% Driven by Advanced Cell Therapy and Biopharmaceutical Innovation | Vantage Market Research
GMP consumables such as culture media, cryopreservation products, single-use bioreactors, and filtration systems are increasingly essential for ensuring product quality, sterility, and regulatory compliance. They support scalable cell expansion, precision manufacturing, and safe clinical outcomes, enabling the broader adoption of cell-based therapies.
https://www.vantagemarketresearch.com/gmp-cell-therapy-consumables-market-3965/request-sample
Vantage Market Research has identified the following companies as the top market players:
https://www.vantagemarketresearch.com/gmp-cell-therapy-consumables-market-3965/request-sample
These leading companies are investing heavily in single-use systems, sterile consumables, and process optimization to meet growing demand for high-quality, GMP-compliant cell therapy products.
"GMP-grade consumables are becoming the backbone of advanced cell therapy manufacturing," said Nneha Rathod Godbole, Founder and CEO at Vantage Market Research. "They enable precise, scalable, and compliant production of cell and gene therapies, helping biopharma companies bring innovative treatments to market safely and efficiently."
The global GMP Cell Therapy Consumables Market is valued at USD 15.05 Million in 2024 and is projected to reach a value of USD 114.4 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 28.9% between 2025 and 2035. The GMP cell therapy consumables market is witnessing rapid growth due to increasing clinical trials, rising approvals for CAR-T, stem cell, and gene therapies, and an expanding pipeline of regenerative medicine products. Key drivers include:
Collectively, these factors are driving robust growth in the GMP cell therapy consumables market.
https://www.vantagemarketresearch.com/gmp-cell-therapy-consumables-market-3965/checkout
The GMP cell therapy consumables market underpins efficiency, quality, and regulatory compliance across autologous and allogeneic therapies, CAR-T, stem cell products, and regenerative medicine. Consumables such as single-use bioreactors, cryopreservation systems, filtration devices, and culture media accelerate production cycles, reduce contamination risk, and ensure batch-to-batch consistency. As demand for scalable, safe, and high-quality therapies rises, resilient access to GMP-grade consumables—media, reagents, bioreactor bags, and filtration units—becomes mission-critical. Disruptions in supply chains, cold chain logistics, or validated consumables can cascade into manufacturing delays, higher costs of goods sold (COGS), and variability in product quality.
For biopharma and cell therapy leaders, this is a strategic inflection point: early investment in GMP-grade consumables, automated processing systems, and resilient supply chains can secure premium manufacturing capabilities, accelerate therapy commercialization, and attract long-term partnerships with ESG- and innovation-focused investors.
In 2024, North America captured 42.6% of the global revenue share, making it a leading region in the industrial enzymes market. Growth is driven by strong adoption of advanced cell and gene therapies, CAR-T, and regenerative medicine products. The U.S. and Canada are innovation hubs, supported by biotech startups, government programs, and major players like Thermo Fisher Scientific, Sartorius, and GE Healthcare. Increasing investments in automated, single-use manufacturing platforms, bioreactors, and cryopreservation systems are reinforcing the region's leadership in high-quality, scalable cell therapy production.
Asia Pacific accounted for significant revenue share in 2024, supported by rapid expansion of biopharma manufacturing, increasing clinical trial activity, and rising demand for cell and gene therapies. China , India , and Japan are investing heavily in GMP-compliant production facilities, driving demand for culture media, single-use bioreactors, filtration systems, and cryopreservation consumables. Leading players like Miltenyi Biotec, Thermo Fisher Scientific, and Sartorius are expanding R&D and manufacturing capacities across the region. Favorable government policies, growing biotech ecosystems, and rising healthcare expenditure position Asia Pacific as a major growth hub in the coming years.
Europe represented about 20% of global revenue in 2024, with growth primarily driven by regulatory frameworks and initiatives promoting advanced therapy medicinal products (ATMPs). Adoption of GMP consumables is strong in CAR-T, stem cell therapies, and regenerative medicine, as manufacturers prioritize sterility, process reproducibility, and patient safety. Germany , France , and the UK are key R&D and manufacturing hubs, while government-backed programs and EU incentives are expected to accelerate the adoption of automated, single-use systems and high-quality culture media.
Latin America accounted for around 6–7% of the global market in 2024, with demand rising for cell and gene therapy manufacturing, clinical trials, and regenerative medicine initiatives.
Brazil is a key growth driver with expanding biopharma infrastructure. Increasing investment in biotechnology, medical research, and hospital-based cell therapy programs is strengthening opportunities for GMP consumables in the region.
The Middle East & Africa (MEA) is poised for steady growth, supported by rising investments in biopharma infrastructure, clinical research, and regenerative medicine initiatives. Saudi Arabia's Vision 2030 and the UAE's healthcare expansion programs are driving demand for GMP-grade culture media, single-use bioreactors, and cryopreservation systems. In South Africa , growing interest in cell therapies and clinical trials is boosting the adoption of automated and closed-system platforms, expanding opportunities across the region.
Cell Culture Media and Supplements led the market in 2024, accounting for 41.4% of total revenue. These consumables are essential for maintaining optimal cell growth, viability, and functionality during ex vivo expansion. High demand is driven by widespread use in stem cell, T-cell, and NK-cell therapies, as well as by growing investments in autologous and allogeneic cell therapy manufacturing. Media and supplements are projected to retain their dominance through 2035, supported by their critical role in ensuring consistent, GMP-compliant cell production.
Stem Cells captured 41.8% of the market in 2024, reflecting their central role in regenerative medicine and research applications. Hematopoietic, mesenchymal, and induced pluripotent stem cells are widely used in preclinical and clinical programs. The increasing number of stem-cell-based therapies in oncology, cardiovascular, and neurology is expected to sustain this segment's growth over the next decade.
Oncology was the largest application segment in 2024, contributing 44.5% of total market revenue. The rise of CAR-T, TCR-T, and NK-cell therapies in hematologic and solid tumors is fueling demand for GMP-grade consumables, including media, separation tools, and cryopreservation systems. Increasing clinical trials and commercial approvals for cell therapies in cancer treatment are expected to further drive this segment.
Browse market data Tables and Figures spread through 245 Pages and in-depth TOC on Market Forecast Report (2025-2035).
https://www.vantagemarketresearch.com/gmp-cell-therapy-consumables-market-3965/checkout
Gain instant access to our exclusive, data-driven dashboard designed for healthcare industry decision-makers, strategists, and market leaders. The platform delivers in-depth statistical insights, segment-wise breakdowns, regional market performance, competitive landscape mapping, company profiles, annual updates, and more. From market sizing to trend analysis and competitive intelligence, this powerful tool serves as a comprehensive solution for informed business decisions.
https://www.vantagemarketresearch.com/industry-report/gmp-cell-therapy-consumables-market-3965
The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com +1 (212) 951-1369. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
Vantage Market Research is a trusted partner to Fortune 500 companies and leading biopharma firms, delivering high-quality market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize on emerging opportunities.
LinkedIn | Twitter | Facebook | YouTube
Priya M
Head of Growth & Strategic Partnerships
224 W 35th St Ste 500, New York, NY 10001,
United States Tel: +1 (212) 951-1369
sales@vantagemarketresearch.com | priya.m@vantagemarketresearch.com
Logo: https://mma.prnewswire.com/media/2758208/Vantage_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gmp-cell-therapy-consumables-market-to-reach-usd-114-4-million-by-2035--with-cagr-28-9-driven-by-advanced-cell-therapy-and-biopharmaceutical-innovation--vantage-market-research-302545212.html